Tempus AI (NASDAQ:TEM) Shares Gap Down – Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s share price gapped down prior to trading on Monday . The stock had previously closed at $37.52, but opened at $33.69. Tempus AI shares last traded at $32.24, with a volume of 1,851,924 shares.

Analyst Upgrades and Downgrades

A number of research firms have commented on TEM. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital lifted their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Tempus AI Stock Down 12.2 %

The company’s 50 day simple moving average is $48.28 and its 200-day simple moving average is $47.27. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling

In related news, COO Ryan Fukushima sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the transaction, the chief operating officer now owns 982,442 shares of the company’s stock, valued at $38,914,527.62. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at $358,780,403.82. This represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 865,041 shares of company stock valued at $35,917,673 in the last 90 days.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the third quarter worth about $30,000. Geode Capital Management LLC grew its holdings in shares of Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after purchasing an additional 539 shares in the last quarter. Vestor Capital LLC purchased a new stake in Tempus AI during the 3rd quarter worth about $153,000. The Manufacturers Life Insurance Company lifted its stake in Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after acquiring an additional 2,765 shares during the last quarter. Finally, Stifel Financial Corp acquired a new position in shares of Tempus AI during the third quarter worth $218,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.